|
Pain management describes a particular set of drugs, analgesics, which are specifically used as therapeutics to control pain in the clinic. As pain affects 1.5 billion people worldwide, these drugs are one of the major segments of the central nervous system (CNS) therapies market. This TriMark Publications report focuses on the role of pain management drugs in clinical use and in drug development for acute pain, chronic pain, neuropathic path and nociceptive pain. The report discusses drug development and targeted therapeutics, as well as their use in clinical trials. New approaches meant to aid in development of drugs for therapeutic use are emphasized. The study also analyzes almost all of the major, specialty and emerging companies known to be marketing, manufacturing or developing pain management treatment products in the U.S. and worldwide. Additionally, this review provides detailed tables, charts and figures with past and projected sales data for the U.S., Europe and other geographic regions.Pain Management Treatment Markets. TABLE OF CONTENTS 1. Overview 6 1.1 Statement of Report 6 1.2 About this Report 6 1.3 Scope of the Report 6 1.4 Objectives 6 1.5 Methodology 7 1.6 Executive Summary 9 2. Introduction 15 2.1 Overview of Pain 15 2.1.1 Acute Pain 15 2.1.2 Chronic Pain 16 2.1.3 Neuropathic Pain 17 2.1.4 Nociceptive Pain 18 2.2 Current Treatment Approaches 23 2.3 Key Problems 26 2.3.1 Side Effects of Therapy 26 2.3.2 Abuse Issues 27 2.4 The Need for New Treatments 37 3. Market Overview 38 3.1 Introduction 38 3.2 Market Analysis 38 3.3 Therapeutic Class 38 3.3.1 Opioids 39 3.3.2 NSAIDs 42 3.3.3 Local Anesthetics 44 3.3.4 Antidepressants 45 3.3.5 Anticonvulsants 46 3.4 Geographical Analysis 46 3.4.1 U.S. 46 3.4.2 Europe 49 3.4.3 Japan 50 3.5 Key Players 51 4. Pipeline Analysis 52 4.1 Introduction 52 4.2 Pain 54 4.3 Neuropathic Pain 55 4.4 Novel Therapeutic Approaches 56 4.4.1 CGRP Antagonists 56 4.4.2 CB2 Agonists 59 4.4.3 Sodium Channel Modulators 61 4.4.4 Calcium Channel Modulators 63 4.4.5 NMDA Antagonists 64 4.4.6 P2x Receptors 65 4.4.7 Trp Channels 67 4.5 Unsuccessful Targets 69 4.5.1 TrpV1 blockers 70 4.5.2 FAAH Inhibitors 71 4.5.3 Other Targets 73 4.6 Novel Formulations 76 4.6.1 Novel Opioids 78 4.6.2 Extended Release Formulations 79 4.6.3 Transdermal Formulations 81 4.6.4 Other Routes 82 4.6.5 Drug Combinations 82 4.7 Overview 85 5. The Changing Competitive Landscape 86 5.1 Overview 86 5.2 The Exit of Major Companies 86 5.3 Major Pharma Players 87 5.3.1 Abbott (AbbVie) 87 5.3.2 Astellas 87 5.3.3 Eli Lilly 87 5.3.4 Johnson & Johnson 87 5.3.5 Novartis 88 5.3.6 Pfizer 88 5.4 Pain Specialty Companies 89 5.4.1 Cephalon (Teva) 89 5.4.2 Endo Pharmaceuticals 89 5.4.3 Grünenthal 89 5.4.4 Hospira 90 5.4.5 Purdue Pharma 90 5.4.6 Mallinckrodt 90 5.5 Emerging Biotechs 91 5.5.1 AcelRx 91 5.5.2 Acura Pharmaceuticals 91 5.5.3 Afferent Pharmaceuticals 92 5.5.4 Algiax Pharmaceuticals 92 5.5.5 Arcion Therapeutics 92 5.5.6 BioDelivery Sciences International 92 5.5.7 Cara Therapeutics 93 5.5.8 Convergence Pharmaceuticals 93 5.5.9 Cytogel Pharma 93 5.5.10 DURECT 93 5.5.11 Egalet a/s 94 5.5.12 iMed 94 5.5.13 KemPharm 94 5.5.14 NeurAxon 95 5.5.15 NeurogesX 95 5.5.16 Newron Pharmaceuticals 95 5.5.17 Nuvo Research 96 5.5.18 Pacira Pharmaceuticals 96 5.5.19 Pain Therapeutics 96 5.5.20 QRx Pharma 96 5.5.21 Relmada Therapeutics 97 5.5.22 Relevare Pharmaceuticals 97 5.5.23 Spinifex Pharma 97 5.5.24 Xenon Pharma 98 5.5.25 Xenoport 98 5.5.26 Zalicus 98 5.5.27 Zogenix 99 For more information kindly visit : Pain Management Treatment Markets. Or Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Toll Free No for USA/Canada : 1-866-279-8368 Email: info@bharatbook.com Website: www.bharatbook.com Follow us on twitter: https://twitter.com/researchbook Follow us on linkedin : http://www.linkedin.com/company/bharat-book-bureau Our Blog : http://blog.bharatbook.com/
Related Articles -
health, pharma, treatment, market data, market research reports,
| 
